Gilead Sciencesvs.Neurocrine Biosciences
GILD vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 9.2× larger than Neurocrine Biosciences by market cap; Gilead Sciences trades at the lower P/E (17.5 vs 26.4); year to date, Neurocrine Biosciences leads (+24.9% vs +5.8%).
Side by side
| GILD | NBIX | |
|---|---|---|
| Market cap | $162B | $17.7B |
| Price | $129.83 | $177.11 |
| Today | −3.7% | −1.9% |
| Return YTD | +5.8% | +24.9% |
| Return 1Y | +13.3% | +31.3% |
| P/E | 17.5 | 26.4 |
| P/S | 5.4 | 5.7 |
| P/B | 6.9 | 5.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Full GILD profile →Neurocrine BiosciencesNBIX
Biopharma focused on neurological and endocrine diseases (Ingrezza).
Full NBIX profile →More comparisons in Biotech & innovation
See where GILD and NBIX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →